What happened
Korea United Pharm filed provisional (unaudited) separate results for Q2 2026: revenue of US$54.4M (+9.7% year on year), operating profit of US$9.36M (+23.6% year on year) and net income of US$26.5M (+3094.2% year on year).
These are preliminary figures the company disclosed ahead of its audited report; the final numbers can differ.
| Revenue | US$54.4M |
|---|---|
| Revenue vs a year earlier | +9.7% |
| Operating profit | US$9.36M |
| Net income | US$26.5M |
| Period | Q2 2026 (separate) |
| Filed | 2026-07-30, Operating results (preliminary) (fair disclosure) |
| Source | DART rcept 20260730800883 → open original filing |
Source: DART. Information only, not investment advice.